203 related articles for article (PubMed ID: 24491572)
1. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
[TBL] [Abstract][Full Text] [Related]
2. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
3. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Macha S; Lang B; Pinnetti S; Broedl UC
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
[TBL] [Abstract][Full Text] [Related]
6. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
11. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Chen LZ; Jungnik A; Mao Y; Philip E; Sharp D; Unseld A; Seman L; Woerle HJ; Macha S
Xenobiotica; 2015; 45(6):520-9. PubMed ID: 25547626
[TBL] [Abstract][Full Text] [Related]
15. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Murphy J; Curtin C; Mamidi RN; Weiner S; Wang SS; Ariyawansa J; Stieltjes H; Wajs E; Di Prospero NA; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):115-28. PubMed ID: 25407255
[TBL] [Abstract][Full Text] [Related]
16. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
17. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
Macha S; Brand T; Meinicke T; Link J; Broedl UC
Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
[TBL] [Abstract][Full Text] [Related]
19. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
20. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
